Is a plunge of 85% or more really in store for one of the biggest Canadian cannabis producers?
The biotech is reeling following the thumbs-down for its experimental DMD drug golodirsen.
The medical device giant beat Wall Street expectations and increased its full-year earnings guidance.
Investors are cheering the drugmaker's settlement in principle of two lawsuits related to its opioid drugs.
Some stocks you merely buy. Others are at the core of your portfolio. These three belong in the latter category.
The charts for these three stocks show the kinds of curves that investors should really like -- trending upward.
The FDA just gave a thumbs-up to rheumatoid arthritis drug Rinvoq. It could become AbbVie's biggest immunology blockbuster after Humira.
Former Canopy Growth co-CEO Bruce Linton says that he's taking advantage of the stock's big sell-off to buy shares. Should investors follow his lead?
FDA approvals for these drugs could translate to billions of dollars for a few companies.
The biotech's present and future might not live up to its past.
Investors, don't bet on U.S. legalization of pot anytime soon.
They're two of the most-followed cannabis stocks on the market. But which is the better pick for long-term investors?
FDA approval of fedratinib could lead to significantly more revenue for the biotech. But even better news could be on the way.
Which stock wins in this big-pharma matchup?
Which stock wins in a matchup between a top cannabis retailer and the leading marijuana REIT?
Two mid-cap biotechs. Two tremendously successful drugs already on the market. But which is the better long-term stock pick?
Disappointing fourth-quarter results are taking a toll on the medical device stock.
There are two possible answers. And neither one of them is good.
The CyberKnife maker missed Wall Street bottom-line estimates and announced disappointing guidance for fiscal 2020.
Investors appear to be worried that the company's growth could be stymied by the FDA's sluggishness in establishing CBD regulations.